
Paul Kirby
Chief Executive Officer & Co-Founder
Get their honest, personalized take on your startup.
Sign in to pitch Paul →At a glance
- Full Name
- Paul Kirby
- Title
- Co-Founder & Managing Partner
- Firm
- Zinc
- Firm Type
- Venture builder and pre-seed investor focused on Science-for-Impact ventures
- Investment Stage
- Pre-seed / start-to-seed
- Check Size
- Initial Zinc investment of up to £250k
- Target Company Profile
- UK Science-for-Impact ventures in health and environment, typically with a strong founding team, IP/science/technology foundation, and a large market opportunity requiring early de-risking and venture-building support
- Sector Focus
- Health, life sciences, biotech, medtech, diagnostics, AI-enabled healthcare, environment, climate, industrial decarbonisation, energy, circular economy, sustainable agriculture, biodiversity, enabling deep technologies
- Geographic Focus
- United Kingdom
- Location
- London, England, United Kingdom
Background
Paul Kirby is Co-Founder and Managing Partner of Zinc, a London-based platform that backs and builds Science-for-Impact ventures. Zinc’s current public positioning is focused on unlocking science and deep technology to address major health and environmental challenges, with investment and venture-building support from the earliest stages through seed.
Before Zinc, Kirby was a partner at KPMG and global head of public services and government. Zinc’s team profile also states that he was Head of the Number 10 Policy Unit, worked across media, education, transport and urban regeneration, served as a Director of Bethnal Green Ventures, and was a Non-Executive Director of the Cabinet Office.
Kirby is also listed by Zinc as a Visiting Professor at the London School of Economics & Political Science. In a January 2026 Zinc article co-authored with Ella Goldner, he described Zinc’s model as a three-pillar platform spanning Investment, Zinc Innovation Partners, and Inflection, intended to help science, talent and capital translate into measurable real-world impact.
Investment Thesis & Focus
- Zinc’s stated investment thesis is to back “innovators leveraging science and deep technology” to solve valuable, pressing problems in health and the environment.
- Kirby and Zinc focus on the earliest and riskiest stage of venture creation, described by Zinc as “from start to seed,” where teams are still validating the problem, de-risking science and technology, developing IP, and forming the commercial proposition.
- Zinc says it backs exceptional entrepreneurs building Science-for-Impact ventures in the UK, with hands-on venture-building support across human capital, intellectual capital, social capital and financial capital.
- Zinc looks for ventures with strong IP, science or technology foundations that can be protected, productised and de-risked.
- Sector priorities include biotechnology, drug development, biomanufacturing, diagnostics, medtech, AI-enabled healthcare delivery, life-sciences tools, energy, industrial decarbonisation, sustainable agriculture and food technologies, circular economy, climate adaptation, water technologies, carbon capture and biodiversity tech.
- Kirby and Ella Goldner wrote in 2026 that Zinc is “not a traditional venture capital firm” but a Science-for-Impact institution operating across investment, innovation and career inflection.
Notable Investments
- Vira Health — Menopause-care venture built through Zinc; TechCrunch reported in 2022 that it had raised $14 million.
- Tandem — Transport-for-workers company built through Zinc; TechCrunch reported in 2022 that it had raised £2 million.
- Unravel Health — Women’s-health diagnostics company using daily at-home hormone monitoring.
- Cellmine — Lithium-ion battery recycling venture developing a scalable, environmentally sound recycling process.
- Cambridge Medixine — AI-enabled mRNA therapeutics company focused on rare and complex disease.
- Clyde Hydrogen Systems — Green hydrogen company developing decoupled electrolysis technology.
- Joey — AI-powered paediatric-care platform connecting parents to paediatric expertise on demand.
- Think Divergent — Healthtech company automating and streamlining adult ADHD assessments.
- Neurolase — Laser- and AI-powered surgical system for high-precision brain surgery; Zinc announced its investment in June 2026.
- KiloGen Therapeutics — Molecular-glue therapeutics platform combining AI, physics and chemistry for oncology targets; Zinc announced its investment in June 2026.
- Anemo Labs — AI-powered “electronic nose” company for early disease detection; Zinc announced its investment in November 2025.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.